Post by
Vincenzovega on Jun 30, 2021 8:47am
Disappointing...
Can someone clarify if the 100,000 units are sold, because it was a conditional sale? Therma hasn't made it official. Their News releases aren't the easiest to understand at times. I see everyone TRYING to dissect their news releases.
April 19, 2021, Conditional Sale: Prior to securing the CE designation, the Company began working to find initial distribution partners and buyers of its AcuVid™ COVID-19 Rapid Antigen Saliva Test once CE approval was received. Through Therma Bright's relationship with Washington DC-based Ridge Global, McWilliams Collective was identified. McWilliams Collective expressed interest in becoming a global distribution partner for North America, LATAM and EMEA regions. The 100,000 CE-approved AcuVid™ COVID-19 Rapid Antigen Saliva Test are targeted for a large European client, on the condition that the Company provides initial saliva test data with demonstrated results of 86%+ specificity and 100% sensitivity, and that production levels are met and delivered during June 2021.
Comment by
mooseslayer on Jun 30, 2021 9:07am
I expect that it will be the next NR. It mentions they must meet test results...check... and that production levels are met and delivered during June 2021. That is the part we don't know. Did they produce and deliver the 100K units. The company really needs to give some guidance on final design of the product and production level capabilities and facilities.
Comment by
spygate on Jun 30, 2021 9:55am
Smokey thats all well and good but if we are hanging our hat on Venowave we will likely see a retreat in the SP again to previous levels. The majority of any new investors here are really only concerned with the progress and success of AcuVid any less than success in that arena will be met with an exit for many, and we know what that will do to the SP.